US FDA raises allergic reaction alert about Merck's antipsychotic Saphris
This article was originally published in Scrip
Executive Summary
US regulators on 1 September warned patients and prescribers about an increased risk of serious allergic reactions with the use of Merck's atypical antipsychotic Saphris (asenapine maleate).